# A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

> **NCT04669171** · PHASE1,PHASE2 · RECRUITING · sponsor: **Enterome** · enrollment: 80 (estimated)

## Conditions studied

- Follicular Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **BIOLOGICAL:** EO2463
- **DRUG:** lenalidomide
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT04669171
- **Lead sponsor:** Enterome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-05
- **Primary completion:** 2029-05-30
- **Final completion:** 2034-05-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04669171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04669171, "A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04669171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*